Transparency

In comments submitted today, FAH reiterated its full support for CMS’s prospective budget-neutral 340B payment policy to continue to pay Average Sales Price (ASP) minus 22.5 percent for 340B-acquired drugs. “We agree with CMS that […]

Read More… from FAH Comments on CY 2022 Medicare OPPS Proposed Rule

[…]

Read More… from FAH Comments on CY 2022 Medicare OPPS Proposed Rule

FAH submitted a letter to three members of President Biden’s Cabinet reiterating support of the No Surprises Act and offering recommendations for implementation of the independent dispute resolution (IDR) process under the law.  FAH President […]

Read More… from FAH Offers Recommendations to Cabinet Secretaries for Independent Dispute Resolution in No Surprises Act